2 research outputs found
Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis
Psoriasis is a chronic immune-dysregulated inflammatory disease and hypovitaminosis D is considered a risk factor. We conducted an online database search to review and meta-analyze the relationship between vitamin D, other bone metabolism parameters, and psoriasis. The efficacy of oral vitamin D supplementation in improving Psoriasis Area and Severity Index (PASI) was also evaluated. Non-original articles, case reports, and animal studies were excluded. Bias risk was assessed according to the Cochrane Collaboration's tool and the Newcastle-Ottawa scale in randomized controlled trials (RCTs) and case-control studies, respectively. Unstandardized mean differences were used for data synthesis. Twenty-three studies reported serum 25 hydroxyvitamin D (25(OH)D) levels in 1876 psoriasis patients and 7532 controls. Psoriasis patients had significantly lower 25(OH)D levels than controls (21.0 & PLUSMN; 8.3 vs. 27.3 & PLUSMN; 9.8, p < 0.00001). Conversely, 450 psoriasis patients had lower levels of parathormone than 417 controls (38.7 & PLUSMN; 12.8 vs. 43.7 & PLUSMN; 16.5, p = 0.015). Four RCTs examined the effect of oral vitamin D supplementation on psoriasis for 173 patients and 160 patients were treated with placebo. No significant differences were found in PASI after 3, 6, and 12 months of supplementation. It is shown that 25(OH)D serum levels are significantly lower in psoriasis, but, although the granularity of RCT methodology may have influenced the pooled analysis, vitamin D supplementation did not seem to improve clinical manifestations
Evaluation of the efficacy of plant sterols supplement sterolip\uae ESI in patients with type IIA hypercholesterolemia in relation to Genetic variants modulating intestinal absorption of cholesterol
Background and aim: Phytosterols (PS) are recommended by European Guidelines for the treatment of hypercholesterolemia. This study aims to evaluate the lipid-lowering activity of a PS supplement
(STEROLIP\uae ESI) in subjects with hypercholesterolemia and the influence of genetic variants involved in cholesterol absorption in the modulation of the individual response to PS. Methods: 60 subjects suffering from hypercholesterolemia were randomized to PS supplement STEROLIP\uae 1.6g/day or to placebo for 6 weeks, and subsequently they were all switched to the supplementation with PS for another 6 weeks. At baseline and every 3 weeks, anthropometric measures and lipid profile were collected. All patients were also genotyped for three genetic polymorphisms involved in intestinal cholesterol absorption (APOE, NPC1L1 and ABCG8). Results: After 3 weeks, TC and LDL-C were significantly lower in PS group. In the 28 patients treated for 12 weeks with PS, we obtained the highest effect after 9 weeks (-8.3% for TC and -12% for LDL-C). We observed a greater reduction of TC and LDL-Cin subjects carrying the E4 allele of APOE gene, in homozygous subjects for the rare allele of NPC1L1 rs2072183 polymorphism and in heterozygous carriers of rare allele rs11887534 in ABCG8 gene than in other genotypes. Conclusion: This study confirms the lipid-lowering effect of PS that is maintained even in the midterm. We highlighted that genetic variants influencing the intestinal cholesterol absorption can contribute to the inter-individual variability of the response of PS supplementatio